Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma
Authors:
Open Access
- 10 May 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1345070
Abstract
Background: Vandetanib is a small-molecule tyrosine kinase inhibitor. It exerts its therapeutic effects primarily in a range of lung cancers by inhibiting the vascular endothelial growth factor receptor 2. However, it remains unclear whether vandetanib has therapeutic benefits in other lung diseases, particularly asthma. The present study investigated the pioneering use of vandetanib in the treatment of asthma.Methods:In vivo experiments including establishment of an asthma model, measurement of airway resistance measurement and histological analysis were used primarily to confirm the anticontractile and anti-inflammatory effects of vandetanib, while in vitro experiments, including measurement of muscle tension and whole-cell patch-clamp recording, were used to explore the underlying molecular mechanism.Results:In vivo experiments in an asthmatic mouse model showed that vandetanib could significantly alleviate systemic inflammation and a range of airway pathological changes including hypersensitivity, hypersecretion and remodeling. Subsequent in vitro experiments showed that vandetanib was able to relax the precontracted rings of the mouse trachea via calcium mobilization which was regulated by specific ion channels including VDLCC, NSCC, NCX and K+ channels.Conclusions: Taken together, our study demonstrated that vandetanib has both anticontractile and anti-inflammatory properties in the treatment of asthma, which also suggests the feasibility of using vandetanib in the treatment of asthma by reducing abnormal airway contraction and systemic inflammation.Keywords
This publication has 56 references indexed in Scilit:
- Duloxetine HCl Alleviates Asthma Symptoms by Regulating PI3K/AKT/mTOR and Nrf2/HO-1 Signaling PathwaysInflammation, 2023
- The Cardiac Na + ‐Ca 2+ Exchanger: From Structure to Function2021
- Nifedipine for primary dysmenorrhoeaCochrane Database of Systematic Reviews, 2021
- Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivityInflammopharmacology, 2021
- A Selective TRPC3 Inhibitor Pyr3 Attenuates Myocardial Ischemia/Reperfusion Injury in MiceCurrent Medical Science, 2020
- Small molecule tyrosine kinase inhibitors in glioblastomaArchives of Pharmacal Research, 2020
- Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management StrategiesAdvances in Therapy, 2013
- The BK channel: a vital link between cellular calcium and electrical signalingProtein & Cell, 2012
- Extracellular high K+ stimulates vesicular glutamate release from astrocytes by activating voltage‐dependent calcium channelsJournal of Cellular Physiology, 2010
- Tyrosine kinase inhibitors: a new approach for asthmaBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2004